Reimagining Medicine

Company overview Financial review Conclusions Appendix References STRATEGY Sandoz has returned to a position of strength; expected spin-off will allow the business more flexibility to pursue its own growth strategy Strengthened Sandoz as a standalone... > Built a strong leadership team with decades of Gx industry experience Expanded pipeline investments 400 Generics and 24 Biosimilars in the pipeline including 4 key launches: adalimumab (approved in EU, launched in US), natalizumab, denosumab, aflibercept Focused on sales execution > Strategic investments in biosimilar capabilities and partnerships including plants in Slovenia and Germany Forged attractive partnerships (e.g. Just-Evotec) to execute on its six strategic levers to drive shareholder value 01 Attractive market fundamentals 04 Margin improvement 02 03 Leadership and scale Multiple growth drivers 05 06 Strong cash flow generation Compelling sustainability story 24 Investor Relations | Q2 2023 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation